개요
세계의 광의학 기술 시장은 2023년에 36억 달러에 이를 전망이며, 2031년에는 67억 달러에 이를 것으로 예측되며, 예측기간 2024-2031년의 복합 연간 성장률(CAGR)은 8.2%를 나타낼 전망입니다.
광의료로 알려진 의료 분야는 빛과 광생물학을 이용하여 질병을 치료합니다. 광의학 기술은 다양한 치료,진단 용도로 채용되고 있습니다. 광의학 기술은 종래의 질병검출방법보다 진행되고 있으며, 종양학, 안과, 치과, 피부과 통증 관리 등 폭넓은 치료 분야의 치료에 사용되고 있습니다.
이 시장을 견인하고 있는 것은 첨단 레이저 기반 치료법의 채용 증가, 미용에 대한 의식 증가, 비침습적인 처치나 기술의 진보에 대한 의식 증가 등의 요인입니다.
촉진요인
고급 레이저 기반 치료 채택 증가
세계의 광의학 기술 시장 수요는 여러 요인에 의해 견인되고 있습니다. 레이저 치료는 다양한 피부 질환에 사용할 수 있는 신기술보다 시행되고 있습니다. 절제 레이저와 비 절제 레이저는 표피와 진피의 다른 수준에 작용하여 많은 피부 질환을 치료할 수 있습니다.
또한 레이저 기술과 인공지능의 통합이 이 시장의 성장을 가속할 것으로 보입니다. 2024년 1월에 출판된 Asclepion laser technology에 따르면, AI와 레이저 장비의 통합은 새로운 시대를 보여주며, 시술자에게 전례 없는 정확도, 효율성, 환자의 미용 목표를 원활하게 달성하는 결과를 제공 합니다.
게다가 업계의 주요 기업들이 새로운 치료와 인가를 도입하면 이 시장의 성장을 가속할 것으로 보입니다. 예를 들어, 2022년 11월, 미국 식품의약국(FDA)은 경증에서 심한 염증성 심상성 여드름 치료에 Accure Acne, Inc.의 Accure Laser System을 승인했습니다. Accure 시스템은 FDA와 CE 마크가 모두 승인된 최초의 1726nm 기반 레이저 장비입니다.
또한, 2024년 4월, ViaLase는 레이저 진보를 위한 4,000만 달러의 자금 조달 시리즈의 종료를 발표했습니다. 펨토 세컨드 레이저에 의한 영상 유도 고정밀도 트래베크렉토미를 실시하는 레이저 시스템의 개발입니다.
억제요인
치료에 따른 부작용과 합병증, 광의료치료의 고비용, 숙련된 전문가의 부족, 한정된 규제 프레임워크과 상환 정책 등의 요인이 시장의 방해가 될 것으로 예상됩니다.
Overview
The global photomedicine technology market reached US$ 3.6 billion in 2023 and is expected to reach US$ 6.7 billion by 2031, growing at a CAGR of 8.2% during the forecast period 2024-2031.
The field of medicine known as photomedicine uses light and photobiology to treat diseases. Technologies in photomedicine are employed for a range of therapeutic and diagnostic applications. Photomedicine technologies are more advanced than traditional disease detection methods and are used to treat a wide range of therapy areas such as oncology, ophthalmology, dentistry, dermatology pain management, and others.
The market is driven by factors such as the increasing adoption of advanced laser-based treatments, increased awareness of aesthetics, and rising awareness about non-invasive procedures & technological advancements.
Market Dynamics: Drivers
Increasing adoption of advanced laser-based treatments
The demand for the global photomedicine technology market is driven by multiple factors. Laser treatments have been implemented over the new technologies available for different skin diseases. Ablative and non-ablative lasers act on different levels of the epidermis and dermis, allowing to treatment of many dermatological conditions.
Moreover, the integration of laser technology and artificial intelligence would drive this market growth. As per Asclepion laser technology publication in January 2024, the integration of AI with laser devices is indicating a new era, offering practitioners unprecedented precision, efficiency, and outcomes that seamlessly achieve their patients' aesthetic goals.
In addition, key players in the industry introducing new treatments and approvals would propel this market growth. For instance, in November 2022, the US Food and Drug Administration (FDA) cleared Accure Acne, Inc.'s Accure Laser System for the treatment of mild to severe inflammatory acne vulgaris. Accure's system is the first 1726nm-based laser device with both FDA and CE Mark clearances.
Also, in April 2024, ViaLase announces the closure of the financing series with $40 million for laser advancement. The development of a laser system that performs femtosecond laser image-guided high-precision trabeculectomy.
Restraints
Factors such as adverse effects & complications associated with the treatment, the high cost of photomedicine procedures, lack of skilled professionals, and limited regulatory framework & reimbursement policies are expected to hamper the market.
For more details on this report - Request for Sample
The global photomedicine technology market is segmented based on technology, application, end-user, and region.
The oncology segment accounted for approximately 54.6% of the global photomedicine technology market share
The oncology segment is expected to hold the largest market share over the forecast period. Skin carcinoma is one of the most dangerous types of cancer & fifth most commonly reported cancer in the world. As per BMC research publication in January 2023, the American Academy of Dermatology (AAD) disclosed that approximately 9,500 people in the United States were diagnosed with skin cancer every day in 2022.
In addition, key players in the market launching innovative technologies in treating various diseases and research studies would propel this market growth. According to an EurekAlert news release in December 2023, ultrafast laser technology could offer improved cancer treatment discovery by the Canadian research team at INRS could lead to more effective use of radiation therapy in oncology.
As per the AAAS publication in March 2022, Biologists and physicists at Lawrence Berkeley National Laboratory (Berkeley Lab) have teamed up to create new opportunities for cancer treatment using laser-generated proton beams.
Moreover, key players launching new products and approvals would drive this market growth. For instance, in January 2024, AngioDynamics, Inc. announced that the United States Food and Drug Administration (FDA) has cleared the Auryon XL Catheter, a 225-cm radial access catheter, for use with the Auryon Atherectomy System in the treatment of Peripheral Arterial Disease (PAD).
North America accounted for approximately 43.4% of the global photomedicine technology market share
North America region is expected to hold the largest market share over the forecast period. The high incidence of skin disorders and cancers in North America, particularly in the United States, drives the demand for advanced photomedicine technologies. According to the American Cancer Society's 2022 update, there were an estimated 1.9 million new cancer cases in the United States, with breast cancer alone accounting for 290,560 new cases.
Moreover, side effects associated with cancer such as hair loss and skin problems drive this market growth. According to the American Hair Loss Association estimated that more than 80 million men and women are suffering from hair loss concerns in the US with a 400% increase in patient demand since the pandemic in 2022.
In addition, major players in this region launched new product launches, and approvals would drive this market growth. For instance, in March 2022, Alma announced the commercial launch of two game-changing additions to Alma's U.S. portfolio of products this year. Alma TED and CBD+ Professional Skincare Solution were launched at the American Academy of Dermatology.
Similarly, in April 2024, Bestqool launched an FDA class-II cleared, durable, and versatile variety of red light therapy (RLT), unique devices designed to handle various skin problems & have medical-grade product certification, like alleviating symptoms of eczema and improving skin health.
Also, in July 2021, Cytrellis announced that the U.S. Food and Drug Administration has cleared their first proprietary product, the ellacor system with Micro-Coring technology, for the treatment of moderate to severe wrinkles in the mid to lower face. This minimally-invasive, first-in-category device safely and effectively removes micro-sized portions of excess skin without surgery, thermal energy, or evidence of scarring.
Similarly, in January 2024, Iridex launches new Iridex 532 and Iridex 577 Lasers in the US market marking 35 years of laser innovation in treating retina disorders & glaucoma.
The major global players in the photomedicine technology market include Candela Corporation, Alma Lasers, Lumenis Be Ltd, PhotoMedex, biolitec Holding GmbH & Co KG, Beurer, Lumibird Medical, Koninklijke Philips N.V., THOR Photomedicine Ltd, and Johnson & Johnson among others.
The global photomedicine technology market report would provide approximately 62 tables, 62 figures, and 182 Pages.
Target Audience 2024
LIST NOT EXHAUSTIVE